59 related articles for article (PubMed ID: 18763172)
1. Matrix metalloproteinase-2 (MMP-2): a major player in the progression of systemic malignancies besides endometrial serous carcinomas.
Kapoor S
Acta Obstet Gynecol Scand; 2008; 87(11):1259. PubMed ID: 18763172
[No Abstract] [Full Text] [Related]
2. MMP-2, TIMP-1, E-cadherin, and beta-catenin expression in endometrial serous carcinoma compared with low-grade endometrial endometrioid carcinoma and proliferative endometrium.
Shaco-Levy R; Sharabi S; Piura B; Sion-Vardy N
Acta Obstet Gynecol Scand; 2008; 87(8):868-74. PubMed ID: 18607832
[TBL] [Abstract][Full Text] [Related]
3. The pattern of CD98 expression is different between uterine serous papillary carcinoma and endometrioid endometrial carcinoma.
Monaghan H; Williams AR
Gynecol Oncol; 2007 Jan; 104(1):264-5. PubMed ID: 17092549
[No Abstract] [Full Text] [Related]
4. The expression of six biomarkers in the four most common ovarian cancers: correlation with clinicopathological parameters.
Lin CK; Chao TK; Yu CP; Yu MH; Jin JS
APMIS; 2009 Mar; 117(3):162-75. PubMed ID: 19245589
[TBL] [Abstract][Full Text] [Related]
5. WT-staining in endometrial serous carcinomas.
Goldstein NS
Int J Gynecol Pathol; 2004 Oct; 23(4):405-7; author reply 407-8. PubMed ID: 15381913
[No Abstract] [Full Text] [Related]
6. Serous and mucinous ovarian tumors express different profiles of MMP-2, -7, -9, MT1-MMP, and TIMP-1 and -2.
Brun JL; Cortez A; Commo F; Uzan S; Rouzier R; Daraï E
Int J Oncol; 2008 Dec; 33(6):1239-46. PubMed ID: 19020757
[TBL] [Abstract][Full Text] [Related]
7. Matrix metalloproteinase-2 involvement in breast cancer progression: a mini-review.
Jezierska A; Motyl T
Med Sci Monit; 2009 Feb; 15(2):RA32-40. PubMed ID: 19182722
[TBL] [Abstract][Full Text] [Related]
8. Wilms' tumor gene 1 (WT1) in endometrial carcinoma.
Coosemans A; Moerman P; Verbist G; Maes W; Neven P; Vergote I; Van Gool SW; Amant F
Gynecol Oncol; 2008 Dec; 111(3):502-8. PubMed ID: 18929401
[TBL] [Abstract][Full Text] [Related]
9. Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity.
Giuntoli RL; Webb TJ; Zoso A; Rogers O; Diaz-Montes TP; Bristow RE; Oelke M
Anticancer Res; 2009 Aug; 29(8):2875-84. PubMed ID: 19661290
[TBL] [Abstract][Full Text] [Related]
10. Syndecan-1 enhances the endometrial cancer invasion by modulating matrix metalloproteinase-9 expression through nuclear factor kappaB.
Oh JH; Kim JH; Ahn HJ; Yoon JH; Yoo SC; Choi DS; Lee IS; Ryu HS; Min CK
Gynecol Oncol; 2009 Sep; 114(3):509-15. PubMed ID: 19539355
[TBL] [Abstract][Full Text] [Related]
11. Differential elevation of matrix metalloproteinase expression in women exposed to levonorgestrel-releasing intrauterine system for a short or prolonged period of time.
Labied S; Galant C; Nisolle M; Ravet S; Munaut C; Marbaix E; Foidart JM; Frankenne F
Hum Reprod; 2009 Jan; 24(1):113-21. PubMed ID: 18812421
[TBL] [Abstract][Full Text] [Related]
12. Effects of doxycycline on serum and endometrial levels of MMP-2, MMP-9 and TIMP-1 in women using a levonorgestrel-releasing subcutaneous implant.
Zhao S; Choksuchat C; Zhao Y; Ballagh SA; Kovalevsky GA; Archer DF
Contraception; 2009 Jun; 79(6):469-78. PubMed ID: 19442784
[TBL] [Abstract][Full Text] [Related]
13. Enhanced systemic matrix metalloproteinase response in Helicobacter pylori gastritis.
Rautelin HI; Oksanen AM; Veijola LI; Sipponen PI; Tervahartiala TI; Sorsa TA; Lauhio A
Ann Med; 2009; 41(3):208-15. PubMed ID: 18979291
[TBL] [Abstract][Full Text] [Related]
14. High serum TIMP-1 is associated with adverse prognosis in endometrial carcinoma.
Honkavuori M; Talvensaari-Mattila A; Puistola U; Turpeenniemi-Hujanen T; Santala M
Anticancer Res; 2008; 28(5A):2715-9. PubMed ID: 19035300
[TBL] [Abstract][Full Text] [Related]
15. Matrix metalloproteinase-2 and matrix metalloproteinase-9 expression in canine and feline meningioma.
Mandara MT; Pavone S; Mandrioli L; Bettini G; Falzone C; Baroni M
Vet Pathol; 2009 Sep; 46(5):836-45. PubMed ID: 19276056
[TBL] [Abstract][Full Text] [Related]
16. The molecular perspective: matrix metalloproteinase 2.
Goodsell DS
Stem Cells; 2000; 18(1):73-5. PubMed ID: 10661578
[No Abstract] [Full Text] [Related]
17. Promoted activation of matrix metalloproteinase (MMP)-2 in keloid fibroblasts and increased expression of MMP-2 in collagen bundle regions: implications for mechanisms of keloid progression.
Imaizumi R; Akasaka Y; Inomata N; Okada E; Ito K; Ishikawa Y; Maruyama Y
Histopathology; 2009 May; 54(6):722-30. PubMed ID: 19438747
[TBL] [Abstract][Full Text] [Related]
18. Activation of matrix metalloproteinase-2 (MMP-2) by membrane type 1 matrix metalloproteinase through an artificial receptor for proMMP-2 generates active MMP-2.
Nishida Y; Miyamori H; Thompson EW; Takino T; Endo Y; Sato H
Cancer Res; 2008 Nov; 68(21):9096-104. PubMed ID: 18974156
[TBL] [Abstract][Full Text] [Related]
19. Menstrual activity of matrix metalloproteinases is decreased in endometrium regenerating after thermal ablation.
Brun JL; Galant C; Delvaux D; Lemoine P; Henriet P; Courtoy PJ; Marbaix E
Hum Reprod; 2009 Feb; 24(2):333-40. PubMed ID: 19049990
[TBL] [Abstract][Full Text] [Related]
20. Matrix metalloproteinase-26 is present more frequently in squamous cell carcinomas of immunosuppressed compared with immunocompetent patients.
Kuivanen T; Jeskanen L; Kyllönen L; Isaka K; Saarialho-Kere U
J Cutan Pathol; 2009 Sep; 36(9):929-36. PubMed ID: 19674198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
